The purpose of this study is to evaluate the outcomes of patients treated with an high dose radiation regimen using either stereotactic hypofractionated or normofractionated radiotherapy for oligometastatic prostate cancer and to establish efficacy (producing a desired result or effect) and safety in this setting.
Study Groups: If the patient found to be eligible to take part in this study, the patient will be assigned to a study group based on the size of the lesion(s) and the discretion of the responsible physician. Up to 71 patients will be enrolled in the study. If the patient is treated with standard radiotherapy, the patient will receive 25 fractions of 2 Gy to the metastases, the treatment duration will be 5 weeks. If the patient is treated with image-guided hypofractionated radiotherapy, the patient will receive 3 fractions of 10 Gy to the metastases, the treatment duration will be 1 week. Radiation Planning and Treatment: During all radiation treatments, the images that are taken during the treatment will be closely analyzed after treatment is over. The patient will have 3 to 25 radiation treatments per metastasis depending on the discretion of the responsible physician. The rest of the radiation treatment planning and treatment delivery appointments will be unchanged. The dose given to the tumor and number of treatments the patient will receive, will be determined by the discretion of the responsible physician, and is not affected by taking part in this study. Follow-Up Visits: After the radiation treatment schedule ends, the patient will return for follow-up visits at the following time points: * At 3 months * Then, every 3 months for 1 year, and then * 1 time a year after that, for as long as possible Additional follow up visits may be scheduled, if the responsible physician thinks they are needed. At these visits, the following tests and procedures will be performed: * Any updates to the medical history of the patient will be recorded and the patient will be asked about any side effects the patient may be having. * The patient's performance status will be recorded. * The patient's complete symptom questionnaires will be reviewed. * The patient will have a clinical examination * The patient will have follow-up imaging (such as an MRI) to check the status of the disease. This is an observational study. Radiation therapy is delivered using CE-certified and commercially available methods.
Study Type
OBSERVATIONAL
Enrollment
73
25\*2 Gy (once a day, 5 days a week)
3\*10 Gy (once a day, 2-3 days a week)
Technische Universität Dresden, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology
Dresden, Saxony, Germany
Universitätsklinikum Tübingen, Department of Radiation Therapy and Radiation Oncology
Tübingen, Germany
Late Toxicity at year 2 after ablatvie radiotherapy
The toxicity will be scored (CTCAE 4.03) at each follow up visit, the status will be recorded by clinical examination and radiological imaging.
Time frame: 24 months after therapy
Early toxicity
The toxicity will be scored (CTCAE 4.03) at 3 months follow up visit, the status will be recorded by clinical examination and radiological imaging.
Time frame: until day 90 after start radiotherapy
Quality of life (QLQ-C30 and QLQ-PR25) during Follow-up
QoL will be assessed with the QoL-Questionaires QLQ-C30 and QLQ-PR25 at baseline, 3, 12 and 24 months after treatment.
Time frame: 24 months after end of therapy
Local control of irradiated tumor manifestations
The tumor response will be evaluated (RECIST) at follow up visit 3,12 and 24 months after end of treatment, the status will be recorded by clinical examination and radiological imaging.
Time frame: 24 months after end of therapy
Therapy-free survival
Therapy-free survival will be assessed as time from start of radiation to start of systemic treatment or androgen deprivation. The status will be assessed at each follow-up visit.
Time frame: 24 months after end of therapy
PSA relapse-free survival
PSA relapse-free survival will be assessed as time from start of radiation to PSA-rise more than 20% above baseline. PSA - value will be assessed by blood testing.
Time frame: 24 months after end of therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.